Cibc World Market Inc. Has $2.28 Million Stock Position in Waters Corporation $WAT

Key Points

• CIBC World Market increased its Waters position by 73.3% in the second quarter, bringing its holdings to 6,085 shares valued at approximately $2.28 million. Institutional investors and hedge funds collectively own 94.01% of the company.
• Waters exceeded quarterly expectations, reporting $3.05 in EPS and $1.65 billion in revenue, while revenue rose 113.3% year over year. The company issued 2026 EPS guidance of $14.45–$14.65.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $420.35 target price; recent targets range as high as $475. Shares opened at $415.07, near their 52-week high of $421.74.

Cibc World Market Inc. boosted its holdings in Waters Corporation (NYSE:WAT - Free Report) by 73.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,085 shares of the medical instruments supplier's stock after buying an additional 2,574 shares during the period. Cibc World Market Inc.'s holdings in Waters were worth $2,282,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Waters in the second quarter worth $3,182,191,000. Norges Bank acquired a new position in Waters during the 4th quarter valued at $265,751,000. Veritas Asset Management LLP boosted its holdings in Waters by 112.3% in the 4th quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier's stock valued at $471,447,000 after purchasing an additional 656,436 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Waters by 509.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 671,103 shares of the medical instruments supplier's stock valued at $254,906,000 after purchasing an additional 561,047 shares during the period. Finally, Marshall Wace LLP grew its position in Waters by 1,611.3% in the 4th quarter. Marshall Wace LLP now owns 581,063 shares of the medical instruments supplier's stock worth $220,705,000 after purchasing an additional 547,109 shares during the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Waters Trading Up 0.2%

Shares of Waters stock opened at $415.07 on Thursday. Waters Corporation has a 52-week low of $282.77 and a 52-week high of $421.74. The firm has a market capitalization of $40.78 billion, a PE ratio of 103.51, a price-to-earnings-growth ratio of 2.41 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29. The company's fifty day moving average price is $385.08 and its two-hundred day moving average price is $347.72.

Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.62 billion. During the same period last year, the firm earned $2.95 EPS. The firm's revenue for the quarter was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, analysts expect that Waters Corporation will post 14.56 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on WAT shares. Evercore restated an "outperform" rating and set a $420.00 price objective on shares of Waters in a report on Wednesday, August 5th. The Goldman Sachs Group increased their target price on shares of Waters from $380.00 to $425.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Barclays lifted their target price on Waters from $425.00 to $460.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Sanford C. Bernstein initiated coverage on Waters in a report on Friday, June 26th. They issued an "outperform" rating and a $435.00 price target for the company. Finally, TD Cowen upgraded Waters from a "hold" rating to a "buy" rating and raised their price objective for the stock from $408.00 to $475.00 in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $420.35.

Insider Buying and Selling

In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the transaction, the director owned 17,808 shares in the company, valued at $7,086,515.52. This trade represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.31% of the stock is currently owned by corporate insiders.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source